BCAB (BIOATLA INC)
Insider Trading Activity
Every open-market purchase and sale reported by BCAB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2026-06-05 | Christian Vasquez | Chief Financial Officer | F | — | — |
| 2026-06-05 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2026-03-12 | Christian Vasquez | Chief Financial Officer | A | — | — |
| 2026-03-12 | Eric Sievers | Chief Medical Officer | A | — | — |
| 2026-03-12 | JAY M PHD SHORT | Chief Executive Officer | A | — | — |
| 2026-03-02 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2026-03-02 | Christian Vasquez | Chief Financial Officer | F | — | — |
| 2026-03-02 | RICHARD A WALDRON | Former Chief Financial Officer | F | — | — |
| 2026-03-02 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2025-12-01 | RICHARD A WALDRON | Chief Financial Officer | F | — | — |
| 2025-12-01 | Christian Vasquez | See Remarks | F | — | — |
| 2025-12-01 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2025-12-01 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2025-09-02 | Christian Vasquez | See Remarks | F | — | — |
| 2025-09-02 | RICHARD A WALDRON | Chief Financial Officer | F | — | — |
| 2025-09-02 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2025-09-02 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2025-06-18 | Susan Moran | Director | A | — | — |
| 2025-06-18 | Scott Andrew Smith | Director | A | — | — |
| 2025-06-18 | Eddie Williams | Director | A | — | — |
| 2025-06-18 | MARY ANN GRAY | Director | A | — | — |
| 2025-06-18 | SYLVIA MCBRINN | Director | A | — | — |
| 2025-06-18 | LAWRENCE STEINMAN | Director | A | — | — |
| 2025-06-03 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2025-06-03 | Christian Vasquez | See Remarks | F | — | — |
| 2025-06-03 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2025-06-03 | RICHARD A WALDRON | Chief Financial Officer | F | — | — |
| 2025-03-13 | RICHARD A WALDRON | Chief Financial Officer | A | — | — |
| 2025-03-13 | Christian Vasquez | See Remarks | A | — | — |
| 2025-03-13 | Eric Sievers | Chief Medical Officer | A | — | — |
| 2025-03-13 | JAY M PHD SHORT | Chief Executive Officer | A | — | — |
| 2025-02-24 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2025-02-24 | RICHARD A WALDRON | Chief Financial Officer | F | — | — |
| 2025-02-24 | Christian Vasquez | See Remarks | F | — | — |
| 2025-02-24 | JAY M PHD SHORT | Chief Executive Officer | F | — | — |
| 2024-09-03 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2024-09-03 | Scott Andrew Smith | Director | F | — | — |
| 2024-08-01 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2024-08-01 | Scott Andrew Smith | Director | F | — | — |
| 2024-07-01 | Eric Sievers | Chief Medical Officer | F | — | — |
| 2024-07-01 | Scott Andrew Smith | Director | F | — | — |
| 2024-06-14 | Susan Moran | Director | A | — | — |
| 2024-06-14 | Eddie Williams | Director | A | — | — |
| 2024-06-14 | SYLVIA MCBRINN | Director | A | — | — |
| 2024-06-14 | MARY ANN GRAY | Director | A | — | — |
| 2024-06-14 | LAWRENCE STEINMAN | Director | A | — | — |
| 2024-06-14 | Scott Andrew Smith | Director | A | — | — |
| 2024-05-31 | Scott Andrew Smith | Director | F | — | — |
| 2024-05-31 | Eric Sievers | Chief Medical Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 58,340 | — |
| — | Director | 45,841 | — |
| — | 10%+ Owner | 44,762 | — |
| — | Chief Medical Officer | 11,840 | — |
| — | Chief Financial Officer | 10,347 | — |
| — | Former Chief Financial Officer | 6,868 | — |
| — | Director | 6,431 | — |
| — | Director | 4,644 | — |
| — | Director | 1,569 | — |
| — | Director | 1,548 | — |
| — | Director | 1,204 | — |
| — | Director | 1,182 | — |
| — | Director | 1,046 | — |
| — | 10%+ Owner | 1 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCAB quote page; the site-wide leaderboard is on the insider transactions hub.